Experimental drug acapatamab targets Hard-to-Treat prostate cancer
NCT ID NCT03792841
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This early-stage study tested a new drug called acapatamab in 212 men with metastatic castration-resistant prostate cancer that had stopped responding to standard therapies. The drug works by helping the body's immune cells attack cancer cells that have a specific marker (PSMA) on their surface. The main goals were to check safety, find the best dose, and see if the drug could shrink tumors or slow the cancer's growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BC Cancer Vancouver
Vancouver, British Columbia, V5Z 4E6, Canada
-
Chris OBrien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
City of Hope at Long Beach Elm
Long Beach, California, 90813, United States
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
El Camino Hospital
Campbell, California, 95008, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Erasmus Medisch Centrum
Rotterdam, 3015 GD, Netherlands
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Krankenhaus der Barmherzigen Brueder Wien
Vienna, 1020, Austria
-
Landeskrankenhaus Salzburg
Salzburg, 5020, Austria
-
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation
Taoyuan, 33305, Taiwan
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577, Japan
-
National Cancer Centre Singapore
Singapore, 169610, Singapore
-
National University Hospital
Singapore, 119074, Singapore
-
Ordensklinikum Linz Elisabethinen
Linz, 4020, Austria
-
Peter MacCallum Cancer Centre
Parkville, Victoria, 3050, Australia
-
Scientia Clinical Research Ltd
Randwick, New South Wales, 2031, Australia
-
Tulane Medical Center
New Orleans, Louisiana, 70112, United States
-
Universitaetsklinikum Allgemeines Krankenhaus Wien
Vienna, 1090, Austria
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
Universite Catholique de Louvain Cliniques Universitaires Saint Luc
Brussels, 1200, Belgium
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Washington University
St Louis, Missouri, 63110, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
-
Yokohama City University Medical Center
Yokohama, Kanagawa, 232-0024, Japan
Conditions
Explore the condition pages connected to this study.